1. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
- Author
-
Jaid Landa, Cinta Hierro, Eva Muñoz-Couselo, Paolo Nuciforo, Joan Seoane, Cristina Viaplana, Joaquín Mateo, Marta Ligero, Ignacio Matos, Enriqueta Felip, Debora Gil, Elena Elez, Guillermo Villacampa, Carlota Rubio-Perez, Rodrigo Dienstmann, Joan Carles, Ana Oaknin, Elena Garralda, Josep Tabernero, Macarena Gonzalez, Raquel Perez-Lopez, Maria Ochoa-De-Olza, Juan Martin-Liberal, Alonso Garcia-Ruiz, Manuel Escobar, Cristina Suarez, Maria Vittoria Raciti, Rafael Morales-Barrera, Irene Brana, Roberta Fasani, and Jordi Rodon
- Subjects
Male ,business.industry ,Immune checkpoint inhibitors ,Middle Aged ,Reviews and Commentary ,Immune system ,Radiomics ,Neoplasms ,Biomarkers, Tumor ,Cancer research ,Humans ,Medicine ,Female ,Radiology, Nuclear Medicine and imaging ,Tomography, X-Ray Computed ,business ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies - Abstract
Background Reliable predictive imaging markers of response to immune checkpoint inhibitors are needed. Purpose To develop and validate a pretreatment CT-based radiomics signature to predict response to immune checkpoint inhibitors in advanced solid tumors. Materials and Methods In this retrospective study, a radiomics signature was developed in patients with advanced solid tumors (including breast, cervix, gastrointestinal) treated with anti-programmed cell death-1 or programmed cell death ligand-1 monotherapy from August 2012 to May 2018 (cohort 1). This was tested in patients with bladder and lung cancer (cohorts 2 and 3). Radiomics variables were extracted from all metastases delineated at pretreatment CT and selected by using an elastic-net model. A regression model combined radiomics and clinical variables with response as the end point. Biologic validation of the radiomics score with RNA profiling of cytotoxic cells (cohort 4) was assessed with Mann-Whitney analysis. Results The radiomics signature was developed in 85 patients (cohort 1: mean age, 58 years ± 13 [standard deviation]; 43 men) and tested on 46 patients (cohort 2: mean age, 70 years ± 12; 37 men) and 47 patients (cohort 3: mean age, 64 years ± 11; 40 men). Biologic validation was performed in a further cohort of 20 patients (cohort 4: mean age, 60 years ± 13; 14 men). The radiomics signature was associated with clinical response to immune checkpoint inhibitors (area under the curve [AUC], 0.70; 95% CI: 0.64, 0.77
- Published
- 2021